Germanygeneva

D"SSELDORF, Germany and GENEVA - - Post-hoc Analysis From CLARITY Study Show That Short-Course Oral Treatment With Cladribine Tablets Significantly Increased the Proportion of Patients who had Absence of Disease Activity Compared With Placebo Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced new data from a post-hoc analysis of the two-year (96-week) placebo-controlled CLARITY(1) Phase III trial using a short-course of Cladribine Tablets (Merck Serono's proprietary investigational oral formulation of cladribine) to treat patients with relapsing-remitting multiple sclerosis (MS).